Filter News

National Institutes of Health (NIH)/National Institute of Allergy And Infectious Diseases (NIAID) Awards Rho Renewal Contract for Inner-City Asthma Research

Published: Nov 19, 2010

Chapel Hill, NC – – The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), has awarded Rho the renewal contract to serve as the statistical and clinical coordinating center (SACCC) for the Inner-City Asthma Consortium (ICAC). Since 2002, the ICAC has been evaluating the effectiveness of asthma treatments in inner-city children and working to understand the underlying causes of the disease. Dr. Herman Mitchell will continue his role as Principal Investigator of the SACCC.

Under this contract, Rho provides statistical, clinical, data management, technical, regulatory, product safety, and administrative expertise to support the design, conduct, and analysis of studies to evaluate the safety and efficacy of therapeutic agents for the treatment of asthma in inner-city children and to examine the underlying mechanisms.

The five-year, $20 million award represents the third major award to Rho from the NIH during 2010. The ICAC-SACCC is one of five NIH coordinating centers in the area of immunology that Rho supports. The others are the Immune Tolerance Network (ITN) Statistical and Data Coordinating Center (SDCC), the Autoimmune Disease Clinical Trials (ADCT) SACCC, the Clinical Trials in Organ Transplantation (CTOT) SACCC, and the Atopic Dermatitis Research Network (ADRN) SACCC. Visit Rho’s website, www.rhoworld.com, to learn more about Rho’s involvement in federally funded research and our exceptional team of scientists and principal investigators.

Rho, a privately-held, contract research organization (CRO) located in Chapel Hill, NC, provides a full range of services across the entire drug development process. For more than 25 years, Rho has been a trusted partner to some of the industry’s leading pharmaceutical, biotechnology, and medical device companies as well as academic and government organizations. Our commitment to excellence, our innovative technologies, and our therapeutic expertise accelerate time to market, maximize returns on investment, and lead to an exceptional customer experience.

This project has been funded in whole with Federal funds from the NIAID, NIH, Department of Health and Human Services, under Contract No. HHSN2722010000521.

Back to news